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Case repOrt
Ipilimumab, nivolumab, and pembrolizumab represent a new 
class of immunotherapeutic drugs for treating patients with 
advanced cancer. Known as checkpoint inhibitors, these drugs 
act to upregulate the cellular and humoral immune response 
to tumor antigens by inhibiting T-cell autoregulation. As a 
consequence, they can be associated with immune-related adverse 
events (irAEs) due to loss of self-tolerance, including rare cases 
of immune-related cytopenias. We performed a retrospective 
clinical chart review, including serologic, hematology, and 
chemistry laboratory results, of two patients who developed 
red blood cell (RBC) autoantibodies during treatment with a 
checkpoint inhibitor. Serologic testing of blood samples from 
these patients during induction therapy with ipilimumab and 
nivolumab, respectively, showed their RBCs to be positive by 
the direct antiglobulin test (IgG+, C3+) and their plasma to 
contain panreactive RBC autoantibodies. Neither patient had 
evidence of hemolysis. Both patients developed an additional 
irAE during treatment. A literature review for patients who had 
developed immune-mediated cytopenia following treatment with 
a checkpoint inhibitor was performed. Nine other patients were 
reported with a hematologic irAE, including six with anemia 
attributable to autoimmune anemia, aplastic anemia, or pure RBC 
aplasia. Hematologic irAEs tend to occur early during induction 
therapy, often coincident with irAEs of other organs. In conclusion, 
checkpoint inhibitors can be associated with the development of 
autoantibodies, immune-mediated cytopenias, pure RBC aplasia, 
and aplastic anemia. Immunohematology reference laboratories 
should be aware of these agents when evaluating patients with 
advanced cancer and new-onset autoantibodies, anemia, and 
other cytopenias. Immunohematology 2017;33:15–21.
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Checkpoint inhibitors are a new class of immunothera-
peutic agents aimed at increasing the host immune response 
against tumor antigens. These include monoclonal antibodies 
against cytotoxic T-lymphocyte–associated antigen 4 
(CTLA-4, CD152), programmed cell death protein 1 (PD-
1, CD279), and programmed cell death ligand 1 (PD-L1, 
CD274) (Table 1). In clinical studies, checkpoint inhibitors 
have been shown to significantly increase survival in patients 
with late-stage cancer. Ipilimumab, a monoclonal antibody 
against CTLA-4, commonly used for patients with advanced 
metastatic melanoma, increases both median and overall 
survival, with some patients showing prolonged clinical 
remission for several years.1–3 Ipilimumab has also been used 
successfully in patients with metastatic prostate cancer and 
in patients with leukemia who relapse after allogeneic stem 
cell transplantation.1,3,4 Likewise, monoclonal antibodies 
against PD-1 have shown equally promising results in 
patients with advanced melanoma, lung cancer, and renal cell 
carcinoma.5–8 At present, there are nearly 100 clinical trials 
involving checkpoint inhibitors being used for patients with 
cancer, including patients with lymphoma, multiple myeloma, 
melanoma, and cancers of the breast, colon, kidney, pancreas, 
ovary, prostate, lung, and head and neck.9
Ipilimumab and other CTLA-4 monoclonal antibodies 
act to increase immune responsiveness to tumor antigens by 
Table 1. Checkpoint inhibitors
Drug class (trade name, manufacturer)
Anti-CTLA-4
Ipilimumab (Yervoy, Bristol-Myers Squibb)
Tremelimumab (AstraZeneca, compassionate use only)
Anti-PD-1
Nivolumab (Opdivo, Bristol-Myers Squibb)
Pembrolizumab (Keytruda, Merck Sharp & Dohme)
Pidilizumab (Medivations, in clinical trials)
Anti-PD-L1
Atezolizumab (Genentech, in clinical trials)
Durvalumab (AstraZeneca, approved bladder cancer)
CTLA-4 = cytotoxic T-lymphocyte–associated antigen 4; PD-1 = 
programmed cell death protein 1; PD-L1 = programmed cell death ligand 1.
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disrupting T-cell autoregulation at the time of initial antigen 
presentation. Normally, T-cell activation is tightly regulated, 
requiring the interaction of two distinct ligand-receptor pairs: 
the T-cell receptor (TCR)–major histocompatibility complex 
(MHC) and CD28-B7.1,5 Initially, antigen-presenting cells 
(APCs), such as macrophages and dendritic cells, bind tumor/
foreign antigens via the MHC and then present the bound 
antigen to the TCR on T-cells. This interaction of MHC-antigen 
with the TCR is the first step in T-cell activation. Subsequent 
binding between B7 on APCs and CD28 on T-cells delivers a 
co-stimulatory signal necessary for T-cell proliferation and 
cytokine secretion. T-cell activation is negatively regulated 
by CTLA-4, which is upregulated upon initial TCR activation 
and blocks the B7-CD28 co-stimulatory signal. Specifically, 
CTLA-4 is a high-affinity receptor for B7 and effectively 
outcompetes CD28 for B7 binding, thereby limiting and 
blunting T-cell activation. Monoclonal antibodies against 
CTLA-4 inhibit this self-regulation, allowing a prolonged 
and amplified T-cell response, enhancing both cellular and 
humoral immunity.1,3
PD-1 and PD-L1 inhibitors, on the other hand, appear 
to act primarily on T-effector cells present in tumor and 
tissues.5,10 PD-1 is expressed on activated T-cells, whereas its 
ligand, PD-L1, is widely expressed on lymphohematopoietic 
cells, epithelial tissues, and on several cancer cell types, such as 
those associated with leukemia, melanoma, and carcinoma. In 
cancer, PD-L1/PD-1 interactions are one mechanism by which 
tumors escape immune surveillance with disease relapse. Like 
CTLA-4-CD28 signaling, the binding of tissue PD-L1 to PD-1 
on activated T-cells transmits an inhibitory signal that blunts 
T-cell activation by promoting T-cell apoptosis and anergy.5 
PD-1 and PD-L1 antibodies block this autoregulatory pathway, 
promoting T-cell expansion and cytokine secretion.
Given their mechanism of action, it is not surprising that 
the most common adverse events associated with checkpoint 
inhibitors are autoimmune phenomena. Up to 70 percent of 
patients receiving ipilimumab are reported to have at least one 
immune-related adverse event (irAE).1,3 The most common 
irAEs are dermatologic with rash and/or pruritus (45–65%); 
gastrointestinal with diarrhea, colitis, and intestinal perforation 
(33%); endocrine disorders due to thyroiditis, hypopituitarism, 
hypophysitis, and adrenal insufficiency (4.5%); and hepatic 
including transaminitis, autoimmune hepatitis, and hepatic 
failure (6%). Other less common irAEs include neurologic 
disorders, ocular inflammation, pancreatitis, pneumonitis, 
systemic vasculitis, immune cytopenias, and acquired 
hemophilia A.1 Laboratory studies often show a lymphocytic 
infiltrate in affected organs, sometimes accompanied by 
circulating autoantibodies.1,3 PD-1 inhibitors are reported to 
have a lower incidence of irAEs, but their irAEs can still be 
life-threatening.5–8,11 IrAEs generally occur within the first few 
months of starting immunotherapy, with an average onset of 
6 weeks.1
Immune cytopenia is considered a rare irAE (1%) and 
includes pancytopenia, immune thrombocytopenia, immune 
neutropenia, aplastic anemia, warm autoimmune hemolytic 
anemia (WAIHA), and pure red blood cell (RBC) aplasia.1,3,4,12–16 
We present two patients who developed strong warm and cold 
RBC autoantibodies during induction immunotherapy with 
ipilimumab and nivolumab, respectively. In addition, we have 
reviewed and summarized the clinical and laboratory findings 
in patients with immune-related cytopenias associated with 
checkpoint inhibitor therapy.
Materials and Methods
Routine ABO and D typing and antibody detection testing 
were performed using a gel-based analyzer (ProVue, Ortho 
Clinical Diagnostics, Raritan, NJ). Samples with abnormal 
test results were referred to the University of Michigan 
Immunohematology Reference Laboratory for further 
investigation using manual methods.
Antibody identification was performed initially by 
gel method (ID-MTS, Ortho Clinical Diagnostics) using 
commercial panel RBCs (0.8%, native, and ficin-treated) per 
the manufacturer’s instructions. Testing for cold agglutinins 
was performed by the tube method (immediate spin, followed 
by a 15-minute room temperature incubation).17 For adsorption 
studies, patient plasma was incubated with washed, enzyme-
treated RBCs (ZZAP; 0.02% ficin, 0.1M dithiothreitol 
final concentration) at 37°C for 30 minutes, followed by 
centrifugation (3100g × 5 minutes) as described.17 Adsorbed 
plasma was tested in parallel with unadsorbed plasma by the 
saline tube method, with readings after 37°C incubation (60 
minutes) and after the indirect antiglobulin test (IAT) using 
polyspecific antihuman globulin (AHG) (rabbit polyclonal IgG, 
mouse monoclonal anti-C3b and anti-C3d; Ortho Clinical 
Diagnostics).
A direct antiglobulin test (DAT) was performed by 
standard tube method using polyspecific AHG (Ortho Clinical 
Diagnostics), monospecific anti-IgG (polyclonal, Ortho 
Clinical Diagnostics), anti-C3b,-C3d (monoclonal blend, 
ImmucorGamma, Norcross, GA), and 6 percent albumin 
control (Ortho Clinical Diagnostics).17 Elution was performed 
on patient RBCs using an acid elution method (Gamma Elu-Kit 
II, ImmucorGamma). The eluate was tested against selected 
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native and ficin-treated RBCs by tube (30 minutes at 37°C; 
Anti-IgG, Ortho Clinical Diagnostics) with polyethylene glycol 
(PEG; GammaPeG, ImmucorGamma) enhancement.17,18
Extended RBC phenotyping was performed by tube 
method using commercial blood typing reagents against C, c, 
E, and e (Rh gel cards, MTS, Ortho Clinical Diagnostics); Fya 
and Fyb (human polyclonal, Ortho Clinical Diagnostics); and 
K, S, s, Jka, and Jkb (IgM monoclonal, ImmucorGamma). All 




The patient was a 65-year-old, group B, D– woman with 
metastatic melanoma to the bilateral groin, with radiologic 
extension into the deep perineum and multiple perineal lymph 
nodes (Table 2). Molecular testing of her tumor showed that 
it was negative for c-KIT mutations but was positive for a 
mutation in B-RAF (V600E), a serine/threonine protein 
kinase. The patient was initially treated with the targeted 
B-RAF inhibitor vermurafenib (Zelboraf; Genentech, South 
San Francisco, CA) for 4 months without clinical improvement 
and with radiologic evidence of disease progression. Her other 
medications included alprazolam, clindamycin, metronidazole, 
and acetaminophen/hydromorphone.
The patient subsequently underwent evaluation to start 
treatment with ipilimumab, an anti-CTLA-4 inhibitor. Clinical 
issues included ongoing bleeding from skin ulcers at the site 
of her bilateral groin masses, resulting in severe anemia 
(hemoglobin [Hb] 6 g/dL, normal 12–16 g/dL). As a result, 
she was transfused with 2 units of RBCs. She was seen 1 
week later for her first scheduled ipilimumab infusion and was 
again severely anemic (Hb 6.7 g/dL) due to blood loss. She 
was transfused an additional 2 units of RBCs. Her antibody 
detection test on both occasions was negative, and there was 
no history of alloantibodies.
The patient was started on ipilimumab at the standard 
induction dose of 3 mg/kg every 21 days for four cycles. 
After her first dose of ipilimumab, she developed a pruritic 
rash on her trunk and lower leg, which was treated with 
over-the-counter medication. The patient was subsequently 
admitted 3 weeks later, just prior to her second ipilimumab 
dose, because of continued bleeding and possible infection 
of her groin masses. Her Hb on admission was 3.7 g/dL. 
The patient again typed as group B, D–, but her antibody 
detection test was now positive. A standard antibody panel 
(gel) identified anti-KEL1. Her extended phenotype was ce 
(rr), KEL:–1, S+s+, Jk(a+b+), Fy(a+ b+). A phenotype of the 
four previously transfused RBC units showed that 1 unit 
was KEL:1. There was no laboratory evidence of a delayed 
hemolytic transfusion reaction: DAT and eluate were negative. 
Other laboratory tests showed a chronically elevated lactate 
dehydrogenase (460–782 IU/L, normal 129–240 IU/L), 
normal haptoglobin (191 mg/dL, normal 22–239 mg/dL), and 
normal total bilirubin (0.5 mg/dL, normal 0.2–1.2 mg/dL). 
A peripheral blood smear showed a mild microcytic anemia 
and polychromasia with no spherocytes, consistent with an 
increased RBC distribution width (18%; normal 11.5–15%), 
mildly decreased mean corpuscular volume (75.1 fL, normal 
79–99 fL), and mean cell Hb concentration (27.7 g/dL, normal 
32–35 g/dL). Her platelet and total white blood cell (WBC) 
counts were normal except for a mild absolute lymphopenia 
(900/μL, normal 1.2–4 K/μL). She was transfused with 4 units 
of KEL:–1, crossmatch-compatible RBCs with an appropriate 
post-transfusion response (Hb 8.0 g/dL). In addition, she 
received localized radiotherapy and cycle 2 of ipilimumab.
The patient returned to the clinic to receive her third 
cycle of ipilimumab. Her Hb was 8.5 g/dL. A new specimen 
showed a positive antibody detection test with both KEL:1 
and KEL:–1 reagent RBCs. The patient’s RBCs reacted by 
the DAT: polyspecific AHG (2+), anti-IgG (1+), and anti-C3 
(2+) with a negative albumin control (Table 3). The patient’s 
plasma was tested with a limited cold agglutinin cell panel, 
consisting of group O adult (n = 2), group B adult (n = 2), group 
O cord cells (n = 1), and an autocontrol; all tests were reactive 
at both immediate spin (1+, tube) and after 15-minute room 
temperature incubation (3+). A standard antibody identifica-
tion panel showed strong panreactivity with 11 of 11 cells in the 
IAT (2+ to 3+; gel); reactivity was enhanced with ficin-treated 
cells (4+). An acid eluate prepared from the patient’s RBCs was 
equally reactive with native (2+) and ficin-treated (2+) group 
O, D–, KEL:–1 RBCs by the PEG-IAT tube method. Because 
of recent transfusions, an autoadsorption was not performed. 
Instead, the patient’s plasma was alloadsorbed four times using 
ZZAP-treated, group O, D– (rr) RBCs, followed by testing 
against a standard antibody panel by saline tube method with 
readings after 60-minute 37°C incubation and after the IAT 
using polyspecific AHG. Adsorbed plasma was reactive with 
only KEL:1 RBCs; no other alloantibody specificities were 
found. In contrast, the unadsorbed plasma control showed 
strong panreactivity (3+) after 37°C incubation, with variable 
reactivity at the IAT-AHG phase (trace to 2+). There was no 
laboratory evidence of hemolysis. A review of her medications 
showed no new medications in the last several months except 
ipilimumab.
Autoantibodies after checkpoint inhibitor immunotherapy
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The patient completed induction therapy without 
further sequelae and did not receive steroids or other 
immunosuppression for any irAE. After 6 months, she was 
transitioned to pembrolizumab, an anti-PD-1 inhibitor (Table 
1), because of disease progression. The patient tolerated 
pembrolizumab (2 mg every 21 days for nine cycles) with 
no documented irAE. A repeat DAT 1 year after receiving 
ipilimumab, as well as pembrolizumab, was negative. The 
patient died of metastatic disease 2 years after completing 
ipilimumab.












(weeks) Treatment Response Other adverse events
12 77/F Melanoma Ipilimumab 10 4 Pancytopenia 10 Steroids Steroid resistant Autoimmune 
hyperthyroidism
IVIG IVIG responsive 
in 8 weeks, 





13 60/M Melanoma Ipilimumab 10 9 Pure RBC aplasia >50 Steroids Steroid resistant Vitiligo
Diarrhea/colitis
HypothyroidismIVIG IVIG responsive
14 68/F Melanoma Ipilimumab 3 3 WAIHA ~11 Steroids Steroid sensitive
14 49/M Melanoma Ipilimumab 3 3 Neutropenia 9–11 Steroids Steroid sensitive
GM-CSF
14 70/F Melanoma Ipilimumab 3 4 Anemia 48 Steroids Steroid sensitive Pruritis
Neutropenia GM-CSF
3 NA/M Prostate 
carcinoma





4 NA Allogeneic stem 
cell transplant
Ipilimumab 10 <4 Immune 
thrombocytopenia
<12 Steroids Steroid sensitive
Resumed 
ipilimumab
15 85/M Melanoma Ipilimumab 3 4 None — — — ANCA+
Nivolumab 3 5 WAIHA 10 Steroids Steroid sensitive
16 52/F Melanoma Ipilimumab NA NA None — — — Autoimmune 
hepatitis
Pembrolizumab NA 3 WAIHA NA Steroids Steroid sensitive, 
relapse at 6 
weeks
Pure RBC aplasia IVIG IVIG responsive
Patient 1 65/F Melanoma Ipilimumab 3 2 Warm and cold 
autoantibodies
7 None None Rash/pruritis
Patient 2 66/M Small cell 
carcinoma lung
Nivolumab 3 4 Warm 
autoantibodies
6 None None Arthritis
IVIG = intravenous immunoglobulin; GM-CSF = granulocyte-macrophage colony stimulating factor; RBC = red blood cell; WAIHA = warm autoimmune 
hemolytic anemia; NA = not available; ATG = anti-thymocyte globulin; ANCA = anti-neutrophil cytoplasmic antibody.
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Table 3. Laboratory findings in patients with therapy-related anemia due to checkpoint inhibitors
Reference Hematologic diagnosis DAT Hemolysis Peripheral blood Bone marrow
16 WAIHA IgG+ Yes Anemia Erythroid hypoplasia
Pure RBC aplasia C3– Reticulocytopenia C3+ T-cell lymphoid infiltrate
14 WAIHA Positive Yes Reticulocytosis Not done
Spherocytes
15 WAIHA IgG+ Yes Reticulocytosis Not done
Agglutination
Spherocytes
14 Anemia NA No Normal RBC Lymphocytic infiltrate








13 Pure RBC aplasia Positive No Anemia* Normocellular marrow
Reticulocytopenia Erythroid hypoplasia
Lymphoid aggregates
Patient 1 Warm and cold RBC IgG+ No Anemia Not done
autoantibodies C3+ Mild lymphopenia
Patient 2 Warm RBC IgG+ No Anemia Not done
autoantibodies C3+ Mild lymphopenia
*Anemia due to ongoing blood loss.
DAT = direct antiglobulin test; WAIHA = warm autoimmune hemolytic anemia; RBC = red blood cell; NA = not available.
Patient 2
The patient was a 66-year-old man with small cell 
carcinoma of the lung, initially treated with cisplatin and 
etoposide (×2), followed by carboplatin and cisplatin (×3) and 
radiation (Table 2). After finding evidence of disease progres-
sion with metastasis, the patient was placed on nivolumab, 
an anti-PD-1 inhibitor, at 3 mg/kg every 2 weeks for 10 
weeks. Within 2 weeks of his first dose, the patient developed 
new-onset joint swelling and pain in both hands, which 
was attributed to nivolumab.19 The patient was prescribed 
ibuprofen (800 mg every 8 hours) and was followed clinically 
without further diagnostic studies. At the time of his fourth 
cycle, the patient complained of fatigue and shortness of breath 
coincident with worsening anemia (Hb 8.2 g/dL). His RBC 
indices, WBC count, and platelet count were within normal 
limits, and there was no objective evidence of hemolysis or 
blood loss. A WBC differential was unremarkable with a 
normal relative and absolute lymphocyte count.
A type and screen was ordered at the time of his fourth cycle 
because of symptomatic anemia (Table 3). His RBC phenotype 
was group A, D– (rr); his antibody detection test was positive. 
His RBCs reacted by the DAT with polyspecific AHG (2+), 
anti-IgG (2+), and anti-C3 (2+). His plasma reacted with 11 
of 11 cells at 37°C by IAT gel (2+); reactivity was enhanced 
by ficin (4+). The autocontrol was positive (1+). Testing his 
plasma with a cold panel showed no reactivity against group O 
cells at either immediate spin or 15-minute room temperature 
incubation. By saline tube method, the patient’s plasma was 
nonreactive after 60-minute 37°C incubation with 6 of 6 
cells and the autocontrol. In a saline tube IAT-AHG, 1–2+ 
reactivity was observed with all cells and the autocontrol (2+). 
An acid eluate was positive with group O, ficin-treated RBCs 
by PEG tube method. The patient’s plasma was adsorbed 
three times with ZZAP-treated autologous RBCs and tested 
against a standard panel at 37°C (60 minutes, saline tube) and 
IAT-AHG. Anti-Jkb was identified in the IAT-AHG; no other 
alloantibody specificities were noted. The patient’s RBCs were 
typed as Jk(a+b–).
A review of the patient’s transfusion records indicated seven 
previous RBC transfusions during the course of chemotherapy 
at another hospital, with the last transfusion 8 months earlier. 
According to this hospital’s records, his antibody detection test 
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was negative on four out of four occasions. The patient’s other 
medications included iron, folate, tamsulosin, ibuprofen, and 
acetaminophen/hydrocodone.
The patient has now received 14 cycles of nivolumab with 
no evidence of disease progression. His course was complicated 
by painful arthritis of his hands early during therapy, which 
has improved with daily ibuprofen and time. The patient did 
not receive steroids or other immunosuppression medications. 
His blood counts remain stable (Hb 8.7–9.5 g/dL) with a 
mild absolute lymphopenia (800–1000/μL) and no evidence 
of hemolysis. There have been no repeat immunohematology 
studies in the last 6 months.
Discussion
Ipilimumab and other checkpoint inhibitors enhance 
cellular and humeral immunity to cancer at the expense of 
immune tolerance to self-antigens.1,5 As a consequence, up to 
60–70 percent of patients receiving ipilimumab experience 
at least one irAE during the course of induction therapy.1,3 
Although most irAEs are mild, approximately 18 percent of 
patients have severe grade 3 or 4 toxicity, with rare fatalities 
(0.6%).1,3,5 Patients with prior antibody-mediated immune 
disorders have had recurrence after starting therapy.12 
Clinicians are cautioned to monitor patients closely for irAEs 
with a low index of suspicion to initiate treatment. Steroids 
remain as the first-line treatment for most irAEs.1 Symptoms 
generally resolve within 4–8 weeks of discontinuing 
treatment.1
Although considered a rare irAE (<1%), immune-mediated 
cytopenias have now been reported in several patients 
(Table 2).3,4,12–16 Anemia is the most common cytopenia and may 
be accompanied by thrombocytopenia and/or neutropenia. 
Anemia may be either hemolytic or hypoproliferative; one 
patient presented with severe anemia due to both WAIHA and 
pure RBC aplasia.16 Anemia is often accompanied or preceded 
by other irAEs of the skin, gastrointestinal, and endocrine 
systems. Like other irAEs, immune cytopenias tend to occur 
during induction therapy (weeks 1–12),4,12,14,15 although there 
are examples of patients developing anemia many months 
after starting immunotherapy.13,14 Interestingly, some patients 
have tolerated ipilimumab with no irAEs, only to develop a 
hemolytic anemia following subsequent treatment with an 
anti-PD-1 inhibitor.15,16 Anemia can be steroid-resistant and 
subject to relapse.
In laboratory testing, over 50 percent of patients with 
irAE anemia will have evidence of a positive DAT, usually 
with IgG (Table 3). In three out of five patients with a positive 
DAT, hemolysis was present.14–16 In four of four patients who 
underwent a bone marrow biopsy, a lymphocytic infiltrate was 
observed.12–14,16 In one case, an atypical lymphoid infiltrate 
was accompanied by an absolute and relative increase in 
circulating lymphocytes composed of NK cells and immature 
CD4+CD8+ lymphocytes.12
Our two patients showed a typical presentation, with 
the development of new erythroid autoantibodies during 
induction therapy. Like many patients (Table 2), our patients 
also developed other irAEs (pruritic rash, arthritis). One 
unusual finding in our two patients was a positive DAT by both 
IgG and C3, and one patient demonstrating cold and warm 
autoantibodies in her plasma. Neither patient had laboratory 
evidence of hemolysis. Patient 1 did have significant anemia 
early in her course that was attributed to chronic blood loss, 
although her Hb stabilized after transfusion and additional 
treatment.
In addition to these two patients, we may have encountered 
a third case of drug-related autoantibodies in a 72-year-
old woman with metastatic adrenal carcinoma. The patient 
presented with a positive DAT (IgG 3+, C3 3+) with a pan-
reactive warm autoantibody (IAT 2+) after participating in a 
PD-L1 trial (atezolizumab) at another institution. Interestingly, 
she was withdrawn from the study trial because of an irAE, 
with markedly elevated liver enzymes.
The possible mechanisms underlying ipilimumab-
associated immune cytopenias may be inferred from studies 
of other common ipilimumab-associated irAEs. Biopsies of 
affected skin, gastrointestinal tissue, and liver typically show 
a lymphocytic infiltrate, sometimes accompanied by other 
inflammatory cells.1,3 This result is consistent with increases 
in CXCL2 and IL8 receptor ligands, which promote leukocyte 
trafficking.4 There is also evidence of upregulation of perforin, 
CD8, Th1 cells, and IFN-γ inducible genes and downregulation 
of IL-10, an antiinflammatory cytokine.1,4,20 In peripheral 
blood, there is a 50 percent decrease in CD4+ Treg cells and 
an increase in CD4+ effector cells and Th17 cells.4,20 The loss 
of Treg cells, in particular, may tip the balance toward an 
immune cytopenia and WAIHA.21 CD4+CD25+ Treg cells 
are believed to play a critical role in the pathogenesis of RBC 
autoantibodies and WAIHA.22–24
In summary, we present two cases of RBC autoantibodies 
in patients receiving immunotherapy with checkpoint 
inhibitors. These two patients were identified because of 
chronic anemia (blood loss, recent chemotherapy) requiring 
a routine type and screen and blood transfusion. Although 
the timing of autoantibody development is consistent and 
highly suspicious for a drug-induced irAE due to checkpoint 
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inhibitor therapy, we cannot definitely prove causality given 
the small number of patients and the retrospective nature 
of this report. As more oncology patients are treated with 
checkpoint inhibitors, it is probable that additional cases will 
be encountered. The true incidence and risk of autoantibody 
formation with these drugs, however, will require larger 
studies and prospective monitoring of patients over the course 
of therapy. Immunohematology reference laboratories should 
be aware of the possibility of cytopenias and autoantibodies in 
cancer and bone marrow transplant patients receiving these 
medications.
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